TY  - GEN
N2  - Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most common form of neuroendocrine neoplasia, but there is no current consensus for the sequencing of approved therapies, particularly with respect to peptide receptor radionuclide therapy (PRRT). Surgical resection is recognized as the only clinically curative measure for GEP-NETs; however, given that these tumors have a propensity to metastasize and the primary tumor may, in some cases, be unresectable, various treatment options have been introduced including PRRT. This review evaluates the data supporting approved therapies for GEP-NETs and the current recommendations for therapeutic sequencing with a focus on PRRT and how sequencing might change with respect to the increasing body of literature regarding PRRT utilization.
DO  - 10.6083/ws859g38c
DO  - DOI
AB  - Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most common form of neuroendocrine neoplasia, but there is no current consensus for the sequencing of approved therapies, particularly with respect to peptide receptor radionuclide therapy (PRRT). Surgical resection is recognized as the only clinically curative measure for GEP-NETs; however, given that these tumors have a propensity to metastasize and the primary tumor may, in some cases, be unresectable, various treatment options have been introduced including PRRT. This review evaluates the data supporting approved therapies for GEP-NETs and the current recommendations for therapeutic sequencing with a focus on PRRT and how sequencing might change with respect to the increasing body of literature regarding PRRT utilization.
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
T1  - A comprehensive review of the therapeutic options for gastroenteropancreatic neuroendocrine tumors with a focus on PRRT and its sequencing
DA  - 2021
AU  - Raymond, Lauren M.
AU  - Korzun, Tetiana
AU  - Kardosh, Adel
AU  - Kolbeck, Kenneth J.
AU  - Pommier, Rodney F.
AU  - Mittra, Erik S.
L1  - https://digitalcollections.ohsu.edu/record/9243/files/Raymond-Lauren-OHSU-ResearchWeek-2021.pdf
PB  - Oregon Health and Science University
LA  - eng
PY  - 2021
ID  - 9243
L4  - https://digitalcollections.ohsu.edu/record/9243/files/Raymond-Lauren-OHSU-ResearchWeek-2021.pdf
KW  - Neuroendocrine Tumors
KW  - Receptors, Peptide
KW  - gastroenteropancreatic neuroendocrine tumor
KW  - (177lutetium-dota(o)tyr3)octreotate
TI  - A comprehensive review of the therapeutic options for gastroenteropancreatic neuroendocrine tumors with a focus on PRRT and its sequencing
Y1  - 2021
L2  - https://digitalcollections.ohsu.edu/record/9243/files/Raymond-Lauren-OHSU-ResearchWeek-2021.pdf
LK  - https://digitalcollections.ohsu.edu/record/9243/files/Raymond-Lauren-OHSU-ResearchWeek-2021.pdf
UR  - https://digitalcollections.ohsu.edu/record/9243/files/Raymond-Lauren-OHSU-ResearchWeek-2021.pdf
ER  -